WASHINGTON, June 4 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has released a draft guidance intended to streamline nonclinical safety studies for biologic and conjugated oncology products, a move the agency says could support cancer drug development while reducing unnecessary animal use. FDA said the recommendations are designed to help sponsors implement more efficient approaches to general toxicology assessments for selected oncology therapies whil . . .

Click here for more information about our products